Souhaitez-vous accéder aux communiqués récents ?
Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.
-
BOSTON, MA and WASHINGTON, DC and SCOTTSDALE, AZ--(Marketwire - May 16, 2012) - June's fourth annual National Employee Wellness Month is once again providing a key platform for leading businesses...
-
CAMBRIDGE, Mass., May 15, 2012 (GLOBE NEWSWIRE) -- Merrimack Pharmaceuticals, Inc. (Nasdaq:MACK), a biopharmaceutical company discovering, developing and preparing to commercialize innovative...
-
body { font-family: Arial, Verdana, Helvetica; font-size: 13px;} table.hugin { border-color:black;} td.hugin { padding: 3px; border-color:black;} GENFIT: GFT505 PROMOTES LIVER FIBROSIS REGRESSION ...
-
body { font-family: Arial, Verdana, Helvetica; font-size: 13px;} table.hugin { border-color:black;} td.hugin { padding: 3px; border-color:black;} GENFIT : GFT505 FAIT REGRESSER LA FIBROSE DU FOIE ...
-
København, 2012-05-09 11:24 CEST (GLOBE NEWSWIRE) -- I henhold til Værdipapirhandelslovens § 28a skal Zealand Pharma A/S indberette transaktioner, der omfatter selskabets aktier og tilknyttede...
-
Copenhagen, 2012-05-09 11:24 CEST (GLOBE NEWSWIRE) -- Pursuant to the Danish Securities Trading Act, section 28a, Zealand Pharma A/S shall announce transactions in the company’s shares and related...
-
BIODIEM ET VIVALIS INITIENT UNE COLLABORATION POUR TESTER LA PRODUCTION DU VECTEUR LAIV SUR LA LIGNEE CELLULAIRE EB66® Melbourne (Australie), Nantes, Lyon (France) - 9 mai 2012 : BioDiem Ltd (ASX:...
-
VIVALIS AND BIODIEM BEGIN COLLABORATION TO TEST PRODUCTION OF THE LAIV VECTOR ON THE EB66® CELL LINE
BIODIEM AND VIVALIS BEGIN COLLABORATION TO TEST PRODUCTION OF THE LAIV VECTOR ON THE EB66® CELL LINE Melbourne (Australia), Nantes, Lyon (France) 9 May 2012: Australian vaccine development company...
-
NEW YORK, May 8, 2012 (GLOBE NEWSWIRE) -- ZIOPHARM Oncology, Inc. (Nasdaq:ZIOP) a biopharmaceutical company with small molecule and synthetic biology approaches to new cancer therapies, today...
-
DUBLIN, Ireland, May 4, 2012 (GLOBE NEWSWIRE) -- Warner Chilcott plc (Nasdaq:WCRX) today announced its results for the quarter ended March 31, 2012. Total revenue in the quarter ended March 31, 2012...